Zentalis Pharmaceuticals LLC

Zentalis Pharmaceuticals Inc. a clinical-stage biopharmaceutical company focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3 an inhibitor of WEE1 a protein tyrosine kinase which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer fallopian tube or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5 an oral small molecule inhibitor of B-cell lymphoma 2 for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader a member of the anti-apoptotic BCL-2 proteins for solid tumors and hematological malignancies. Zentalis Pharmaceuticals Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings LLC; Pfizer Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York New York.